



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: John S. PATTON)

Atty. Docket No.: 0002.12)

Examiner: David LUKTON)

Application No.: 09/577,264)

Group Art Unit: 1654)

Filed: 05/22/2000)

Title: PULMONARY DELIVERY OF ACTIVE)
FRAGMENTS OF PARATHYROID)
HORMONE)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on 26 Jul 2006 (AT)

Signed: 

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

Attorney Docket No. 0002.12

- ☐ within three months of the filing date of a national application or an RCE; within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action on the merits (whichever event occurs last);
- ☐ more than three months from the filing date of an application and after the mailing date of a first Office action on the merits, but before the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311 (whichever occurs first), and is accompanied by:
- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or
 - ☐ one of the following statements as specified in 37 CFR 1.97(e) that:
 - ☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or
- ☐ after the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311, but on or before the payment of the issue fee, and is accompanied by each of:
- ☐ the following petition:

Applicant hereby requests consideration of the accompanying information disclosure statement;
 - ☐ the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and
 - ☐ one of the following statements as specified in 37 CFR 1.97(e) that:
 - ☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement.

☒ Applicants submit herewith a copy of reference cited in the prior IDS filed 23APR2001, which was inadvertently omitted from the mailing. Accordingly applicants believe no fee is due. If such a fee is necessary, applicants hereby authorize the fee to be charged to Deposit Account Number 500348.

☐ Attached is Check No. _ in the amount of \$0.

☐ Please charge the amount of \$___ to Deposit Account 500348


☒ If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.

Respectfully submitted,


NEKTAR THERAPEUTICS

Dated: 26 July 2006

By:


Michael J. Mazza
Reg. No. 30,775

NEKTAR THERAPEUTICS
150 Industrial Road
San Carlos, CA 94070
(650) 631-3100



Form PTO/SB/08B (Modified) Information Disclosure Statement By Applicant <i>(Use Several Sheets if Necessary)</i>	Atty Docket No.: 0002.12	Application No.: 09/577,264
	Applicant: John S. PATTON	
	Filing Date: 05/22/2000	Group: 1654

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	A	PATTON, "Deep-lung delivery of proteins", Modern Drug Discovery, Sept./Oct. 1998; pp. 19-28.
	B	
	C	
	D	
	E	
	F	
	G	
	H	
	I	
	J	
	K	
	L	
	M	
	N	
	O	
	P	
	Q	
	R	

Examiner:	Date Considered:
------------------	-------------------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.